Treatment of osteoporosis with recombinant parathyroid hormone, utilisation of total body DXA to observe treatment effects on total body composition and factors determining response to therapy

Purpose Recombinant parathyroid hormone (rPTH) increases bone mineral density (BMD). However, certain other potential effects of rPTH remain to be studied. The aim of this study is to identify whether bone turnover markers, relevant biochemical parameters or total body fat and muscle composition affect the response to rPTH and to establish if these parameters in particular change during treatment.